Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                FDA’s Labeling Resources for Human Prescription Drugs

FDA’s Labeling Resources for Human Prescription Drugs

                        Prescribing Information Resources
          Patient Labeling Resources
          Carton and Container Labeling Resources
          Selection of Appropriate SPL Codes for Human Prescription Drug Labeling
          Generic Drugs - Specific Labeling Resources
          Biological Products - Specific Labeling Resources
          Frequently Asked Questions about Labeling for Prescription Medicines
          Prescription Drug Labeling Contact Information Home
          Drugs
          Guidance, Compliance, & Regulatory Information
          Laws, Acts, and Rules
          FDA’s Labeling Resources for Human Prescription Drugs
          Patient Labeling ResourcesFDA’s Labeling Resources for Human Prescription Drugs Patient Labeling Resources
  
  					For Industry
	
    Share
    Post
    Linkedin

    Email
    PrintOn this page

Who is the audience for this webpage?
	What are Instructions for Use?
	What are Medication Guides?
	What are Patient Package Inserts?
	What is Patient Medication Information?
	Contact information


Who is the audience for this webpage?

FDA’s patient labeling specific resources on this webpage are primarily directed to industry staff who develop patient labeling for prescription drugs. For assistance on how to navigate this webpage and the associated FDA labeling resource webpages for human prescription drugs see video. For more information about:

Other prescription drug labeling resources for industry such as those for the Prescribing Information, carton and container labeling, generic drug labeling, biological product labeling, labeling databases, and product databases visit FDA’s Labeling Resources for Human Prescription Drugs.
	Drug labeling resources for healthcare professionals, patients, and caregivers, visit Frequently Asked Questions about Labeling for Prescription Medicines.What are Instructions for Use?

The Instructions for Use (IFU) is patient labeling that can be part of FDA-approved prescription drug labeling for a biologics license application (BLA), a new drug application (NDA), or an abbreviated new drug application (ANDA). The IFU is developed by applicants for patients (or their caregivers) who use prescription drugs that have complicated or detailed patient-use instructions. The IFU provides detailed, action-oriented, step-by-step written and visual instructions for the patient on how to use the drug including instructions on preparation, administration, handling, storage, and disposal.  The IFU is developed by the applicant, reviewed and approved by FDA, and provided to patients (or their caregivers) when the drug is dispensed.  Some IFUs are not approved by the FDA.  IFU resources include:

Instructions for Use - Patient Labeling for Human Prescription Drug and Biological Products (final guidance)
	An additional guidance that has specific recommendations for the IFU: Metered Dose Inhaler and Dry Powder Inhaler Drug Products - Quality Considerations (draft guidance)Below see an example IFU template that provides a general overview of the IFU (this IFU does not contain any product-specific information).

instructions for use
What are Medication Guides?

A Medication Guide is patient labeling that is part of the FDA-approved prescription drug labeling for certain prescription drugs when the FDA determines that:

Patient labeling could help prevent serious adverse reactions
	The drug has serious risk(s) (relative to benefits) of which patients should be made aware because information concerning the risk(s) could affect patients' decision to use, or to continue to use, the product, or
	Patient adherence to directions for use is crucial to the drug’s effectiveness.Medication Guides (MGs) are developed by applicants, approved by FDA, and required to be distributed to patients.  MG resources include:

MG regulations available at 21 CFR 208
	Medication Guides - Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS) (final guidance)
	FDA Drug Information Webinar: Distribution of Medication Guides
	A guidance that has specific recommendations for the MG is the following:  Child-Resistant Packaging Statements in Drug Product Labeling (final guidance).Below see an example MG template that provides a general overview of the MG (this MG does not contain any product-specific information). Consider using the enclosed Sample Template for Medication Guides when developing a Medication Guide (this sample template may not contain all the Medication Guide requirements or guidance recommendations).

medication guide template
What are Patient Package Inserts?

A Patient Package Insert (PPI), also known as “Patient Information” is patient labeling that can be part of the FDA-approved prescription drug labeling. Certain PPIs are developed by the manufacturer and approved by the FDA.

PPIs are required for oral contraceptives and estrogen-containing products, and these PPIs are required to be dispensed with each prescription:

PPIs for oral contraceptives (21 CFR 310.501)
	PPIs for estrogens (21 CFR 310.515)PPIs for other prescription drugs are submitted to the FDA voluntarily by the manufacturer and approved by the FDA, but their distribution is not mandated.

A guidance that has specific recommendations for the PPI is the Child-Resistant Packaging Statements in Drug Product Labeling (final guidance).

Below see an example PPI template that provides a general overview of the PPI (this PPI does not contain any product-specific information).  The headings in this example PPI may not be applicable to all PPIs. Consider using the enclosed Sample Template for Patient Package Insertswhen developing a PPI (this sample template may not contain all the PPI requirements or guidance recommendations).

patient package insert
What is Patient Medication Information?

FDA published a proposed rule, Medication Guides: Patient Medication Information in May 2023. Under the proposed rule, FDA is proposing to amend its human prescription drug labeling regulations to require a new type of Medication Guide — Patient Medication Information (PMI) — for prescription drugs used, dispensed, or administered on an outpatient basis, as well as for blood and blood components transfused in an outpatient setting. When the rule is finalized, PMI will:

Contain essential information that patients need to know about the prescription drug,
	Be an FDA-approved one-page document with standardized format and content requirements.For additional information on the proposed PMI rule visit the Patient Medication Information webpage.

Contact Information

For specific application or supplement questions or for general questions about prescription drug labeling, please visit Prescription Drug Labeling Contact Information.

For general questions about patient labeling or this website please email CDEROMP@fda.hhs.gov.

                                                                                  Content current as of:
      09/18/2023
              
              
Regulated Product(s)
		 DrugsFDA’s Labeling Resources for Human Prescription Drugs

          
                        Prescribing Information Resources
          Patient Labeling Resources
          Carton and Container Labeling Resources
          Selection of Appropriate SPL Codes for Human Prescription Drug Labeling
          Generic Drugs - Specific Labeling Resources
          Biological Products - Specific Labeling Resources
          Frequently Asked Questions about Labeling for Prescription Medicines
          Prescription Drug Labeling Contact Information
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop